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Summary
 
The brain is an immunoprivileged organ isolated from the peripheral immune system. How-
ever, it has been shown that resident cells, notably astrocytes and microglia, can express numer-
ous innate immune molecules, providing the capacity to generate a local antipathogen system.
Perforin is a cytolytic protein present in the granules of cytotoxic T lymphocytes and natural
killer cells. Expression in cells other than those of the hemopoetic lineage has not been de-
scribed. We report here that fetal astrocytes in culture (passages 2 to 15), astrocytoma, and adult
astrocytes expressed perforin. Reverse transcriptase polymerase chain reaction followed by
Southern blot was carried out using multiple specific primers and all cDNAs were cloned and
 
sequenced. Human fetal astrocyte perforin cDNA sequence was 
 
z
 
100% identical to the re-
ported perforin cDNA cloned from T cells. Western blot analysis using monoclonal and poly-
clonal antiperforin peptide antibodies revealed a protein of 65 kD in both human fetal astrocyte
 
and rat natural killer cell lysates (
 
n
 
 
 
5
 
 4). Immunostaining followed by FACS
 
Ò
 
 and confocal and
electron microscopy analysis revealed that perforin was expressed by 40–50% of glial fibrillary
acidic protein positive cells present in the fetal brain culture (
 
n
 
 
 
5
 
 11). Perforin was not local-
ized to granules in astrocytes but was present throughout the cytoplasm, probably in association
with the endoplasmic reticulum. Perforin was not detected in normal adult brain tissue but was
present in and around areas of inflammation (white and grey matter) in multiple sclerosis and
neurodegenerative brains. Perforin-positive cells were identified as reactive astrocytes. These
findings demonstrate that perforin expression is not unique to lymphoid cells and suggest that
perforin produced by a subpopulation of astrocytes plays a role in inflammation in the brain.
 
C
 
ytotoxic T lymphocytes (CTLs) and NK cells contain
an impressive armory within their granules. Preemi-
nent among these weapons is perforin, a granule protein
which polymerizes in the membranes of target cells to form
pores that contribute directly or indirectly to target cell de-
struction (1–3). Expression of perforin by nonlymphoid
cells has not been reported. The importance of perforin in
immune surveillance has been graphically demonstrated in
mice in which the perforin gene has been deleted. These
animals are more susceptible to viral infections and to the
development of tumors (4, 5).
The brain is shielded from the immune system and con-
tains few lymphoid cells. Therefore, defense within the
brain must involve resident cells. Brain microglia subserve
some of the roles of lymphoid cells and are considered to
be the resident macrophage of the brain (6). However, as-
trocytes are by far the most abundant glial cell type in the
brain and their potential role in defense has been neglected.
We and others have recently shown that astrocytes express
many properties usually associated with immune cells (7). For
 
example, astrocytes can synthesize all of the components of
the complement system, providing a source of complement
in the brain, and express complement receptors mediating
responses to complement activation products (7). In a re-
cent survey of tissue-expressed genes by partial DNA se-
quencing to generate expressed sequence tags, expression
of perforin mRNA was noted in the human brain (refer-
ence 8; sequence data available from EMBL/GenBank/
DDBJ under accession number AA351844). Given the
paucity of lymphoid cells in the brain, we were provoked
to examine whether brain cells might express perforin.
 
Materials and Methods
 
Cell Cultures and Tissues.
 
Primary cultures and maintenance
of cell lines were carried out according to the protocol described
previously (9). Human fetal brains were obtained from the Medi-
cal Research Council (MRC) Fetal Tissue Bank (Hammersmith
Hospital, London, UK) and used as a source of fetal astrocytes.
Cells in passages 2–15 were used in this study. Normal adult tem-
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poral lobe tissue was obtained fresh from biopsies of patients
(three cases) undergoing therapeutic resection for intractible epi-
lepsy. These were used for culture of adult glial cells as previously
described (10). Glial cells from adult brain were seeded on poly
 
l
 
-lysine coated glass coverslip and after 3 wk in culture were used
for immunocytochemistry. Two human glioma cell lines (CB193
and T98G) were also used in this study to confirm the expression
of perforin by astrocyte-derived cell lines. CB193 was from Dr.
B. Delpech (H. Becquerel Institute, Rouen, France) and T98G
was from the American Type Culture Collection (ATCC; Rock-
ville, MD). Human cell lines, Raji (B lymphocyte), THP1 (mono-
cyte), and K562 (erythroleukemia) were obtained from the Euro-
pean Collection of Animal Cell Cultures (Salisbury, UK). Human
YT (NK cell line) was obtained from Dr. G. Griffiths (University
College of London, London, UK) and was cultured in the pres-
ence of recombinant interleukin 2. The rat NK cell line was
available in-house and was also cultured in cytokine-supple-
mented medium. Brains from 1-d-old rats were used as a source of
rat astrocytes. Mouse CTTL-2 cell line was obtained from Dr. J.
Matthews (Department of Medicine, University of Wales College
of Medicine (UWCM), Cardiff). Samples of normal human brain
tissues (from three individuals with nonneurological causes of
death and with postmortem delay of 
 
,
 
12 h) were provided by the
Department of Neuropathology (Dr. J.W. Neal, Neuropathology
Department, UWCM). Frozen brain tissue sections from four
cases of multiple sclerosis (MS;
 
1
 
 three semiacute plaques and one
chronic plaque) were obtained from Dr. Jia Newcombe (MS Soci-
ety Laboratory, London, UK). Frozen brain tissue samples from
three cases of Pick’s disease (PD) with Pick inclusion bodies and
from three cases of Alzheimer’s disease (AD) with severe 
 
b
 
 amy-
loid deposits were obtained from Dr. Nigel J. Cairns (MRC AD
Brain Bank, Institute of Psychiatry, London, UK). Frozen brain
tissue (caudate nucleus) from individuals with Huntington’s dis-
ease (HD) with a high Vonsattel grade (grade 4, average of 60
CAG repeats) were diagnosed and obtained locally from Dr. J.W.
Neal. All frozen brain tissues were stored at 
 
2
 
40
 
8
 
C.
 
Antibodies and Cytokines.
 
The mouse monoclonal antiper-
forin antibody, a gift from Dr. G. Griffiths, was generated against
a 16-amino acid perforin peptide encompassing residues 285–300
in human perforin, KHKMTASFHQTYRERH (14). This anti-
body detects human mouse, and rat perforin in the native but not
the polymerized form. The polyclonal rabbit antiperforin peptide
antibody was generated in-house against the COOH terminus of
human perforin (LGEPPGNRSGAVW, residues 522–534). Nei-
ther of the chosen perforin peptides had any homology with the
complement components C7, C8, and C9, and neither the mono-
clonal nor the polyclonal antibody recognized any bands in West-
ern blots of human sera. Polyclonal rabbit anti–glial fibrillary
acidic protein (GFAP) (B5) was obtained from Dr. J. Newcombe
and monoclonal antibodies against brain-specific antigens (clone
GA5
 
IgG1
 
 anti-GFAP; clone NE14
 
IgG1
 
; antineurofilament 200) were
obtained from Sigma Chemical Co. (Poole, Dorset, UK). Mouse
antigalactocerebroside (GC) was obtained from Dr. S. Piddlesden
(UWCM). Mouse anti-neuron-specific enolase, (NSE; clone
BBs/NC/VI-H14
 
IgG1
 
) was obtained from Dako Ltd. (High Wy-
combe, Bucks, UK). Monoclonal antimicroglia and antimacro-
phage (clone LN3
 
IgG1
 
, anti-HLA class II; clones KP1
 
IgG1
 
, PGM1
 
IgG3
 
,
EBM11
 
IgG1
 
, anti-CD68; and clone My-4
 
IgG2b
 
, anti-CD14) were
from Biotest (Solihull, UK), Dako Ltd., and Coulter (Luton,
Beds, UK), respectively. Monoclonal anti-CD44 (clone BRIC
235
 
IgG2b
 
) and anti-CD59 (clone B229
 
IgG2b
 
) were from International
Blood Group Reference Laboratory (Herts, UK). Mouse anti-
CD56 (clone NCAM
 
IgG2b
 
) and anti-CD57 (clone HNK1
 
IgM
 
)
were from Becton Dickinson (Oxford, UK). The hybridoma
anti–human CR3 (CD11b, clone OKM1
 
IgG2b
 
) was purchased
from the ATCC, and tissue culture supernatant was used as a
source of antibody. Alkaline phosphatase– and peroxidase-conju-
gated goat anti–mouse and anti–rabbit immunoglobulins were
from Sigma and Biorad (Hertfordshire, UK), respectively, FITC-
and rhodamine-conjugated goat anti–rabbit immunoglobulins
were from Harlan SeraLab (Crawley Down, Sussex, UK) and
Jackson (Stratech Sci. Ltd., Luton, Beds, UK), respectively.
FITC-conjugated donkey anti–mouse immunoglobulins were
from Jackson and used with the rhodamine-conjugated goat anti–
rabbit immunoglobulins in all double immunofluorescence experi-
ments. RPE-conjugated goat anti–mouse immunoglobulin was
from Dako and was used for FACS
 
Ò
 
 analysis with the FITC-con-
jugated goat anti–rabbit immunoglobulins. Recombinant cyto-
kines (IFN-
 
g
 
, IL-1–
 
b
 
, and TNF-
 
a
 
) were the gift of Hoffman la
Roche (Nutley, NJ) and were used at 200 IU/ml for 24 h to
stimulate fetal brain astrocyte cultures. Recombinant IL-2 was
provided by Dr. J. Matthews (Medicine Department, UWCM).
 
Immunocytochemistry and Western Blotting.
 
The preparation of
frozen tissue sections and all techniques and reagents for immu-
nocytochemistry analysis (diaminobenzidine [DAB]/immunoper-
oxidase, 5-bromo-4-chloro-3indolyl phosphate [BCIP]/nitroblue
tetrazolium [NBT]/immunoalkaline phosphatase, and FITC/rhoda-
mine indirect immunofluorescence) have been previously de-
scribed (9–11). Immunodetection of perforin within adherent
cells and cells in suspension was carried out by FACS
 
Ò
 
 and confo-
cal and immunoelectron microscopy analysis (10, 11). The
FACS
 
Ò
 
 analysis protocol was adapted to detect intracellular anti-
gen (perforin and GFAP) and included a cell permeabilization
step before cell staining. Cells in suspension were fixed with 10%
formaldehyde for 10 min at 4
 
8
 
C and after two washes in PBS cells
were permeabilized with 0.05% of NP-40 in PBS with 1% BSA
(NP40/PBS/BSA). After three washes with PBS, cells (10
 
5
 
 cells/
analysis) were incubated for 1 h at 4
 
8
 
C with primary antibodies
followed by fluorochrome-conjugated secondary antibodies, all
diluted in NP40/PBS/BSA. Nonspecific binding of antibodies to
cells and tissue sections was assessed in all immunocytochemical
analyses using irrelevant monoclonal and polyclonal antibodies.
Unstimulated fetal and adult astrocytes in culture were negative
for complement factor H (FH), complement C4b binding protein
(C4bp), CD11b, CD68, and C-reactive protein (CRP) when using
mouse  anti-FH (clone OX24
 
IgG1
 
, from Dr. R. Sim, MRC
Immunochemistry  Unit, Oxford, UK), Mouse anti-C4bp (clone
H1C6
 
IgG1
 
, from Dr. A. Ischenko, Institute of Highly Pure Bio-
preparations, St. Petersburg, Russia), mouse anti-CD11b (clone
OKM1), and rabbit anti-CRP (Calbiochem, Nottingham, UK),
respectively. These results confirmed our previously published
observations (9, 10, 12). No specific staining was obtained when
brain tissue sections were incubated with mouse and rabbit anti-
complement C4bp (Dr. M. Colomb, Grenoble, France), used
here as irrelevant control antibodies. Fetal and adult astrocytes were
GFAP
 
high
 
, CD44
 
high
 
, CD56
 
high
 
, and CD59
 
high
 
, and were negative
for CD68, CD11b, GC, and NSE. All these cellular markers were
used to identify the astrocyte cell population in vitro and in situ.
 
1
 
Abbreviations used in this paper:
 
 AD, Alzheimer’s disease; BCIP, 5-bromo-
4-chloro-3indolyl phosphate; C4bp, C4B binding protein; CRP, C-reac-
tive protein; DAB, diaminobenzidine; FH, complement factor H; GC,
galactocerebroside; GFAP, glial fibrillary acidic protein; HD, Hunting-
ton’s disease; MS, multiple sclerosis; NBT, nitroblue tetrazolium; NSE,
neuron-specific enolase; PD, Pick’s disease; RT, reverse transcriptase. 
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Figure 1. RT-PCR analysis and
sequencing of astrocyte perforin
cDNA. (A) Astrocyte total RNA
were obtained from fetal astrocyte
cultures (passage 3) and RT-PCR
was carried out as previously de-
scribed (9) using different primer
pairs (20 bp) to amplify different
regions of the perforin cDNA. The
specificity of each cDNA prod-
uct was assessed by Southern blot-
ting using an FITC dUTP per-
forin cDNA probe (see Materials
and Methods). The portion of
the perforin cDNA amplified by
the different primer pairs is given
for each lane at the top of the
figure. (B) Schematic representa-
tions of the sequence of perforin
(protein and cDNA). The posi-
tions of the epitopes for the anti-
bodies used in this study (mono-
clonal and polyclonal antipeptide)
are indicated in i. ii shows the position of the primers and probes derived from CTL perforin cDNA (reference 13, sequence data available under EMBL/
GenBank/DDBJ under accession number M28393) and used in the analysis of astrocyte perforin cDNA. iii illustrates the astrocyte perforin cDNA sequence
obtained from the cloned RT-PCR products (hatched area) on the full-length perforin cDNA. Together, these products provided .90% of the astrocyte
perforin cDNA coding region. Six different batches of fetal astrocytes were used in separate experiments with identical final results. The sequence was
consistent and differed from that of the published CTL perforin cDNA sequence (13) by a single residue (C490T).
 
Immunocytochemical analyses were performed using either a
DMLB Leica immunofluorescence/bright field microscope or a
Leica TCS confocal laser scanning microscope (CLSM; Leica,
Heidelberg, Germany). For CLSM, frame scanning was per-
formed at 
 
3
 
400 or 
 
3
 
1,000 magnification and 12 optical sections
were collected per field at 0.2 
 
m
 
m intervals from the bottom to
the top of the cell. Immunogold staining analysis was performed
on a Philips (Eindhoven, The Netherlands) transmission electron
microscope. Preparation of cell lysates and the protocol for West-
ern blot were previously described in detail (9).
 
Reverse Transcriptase PCR, Cloning, Sequencing, and Southern
Blotting.
 
Total RNA from positive (human CTL cell line, YT)
and negative (THP1, K562, Raji) control cell lines were used to
test the specificity of all perforin primers by reverse transcriptase
(RT) PCR. All samples were subjected to RT-PCR for 
 
b
 
-actin
and glyceraldehyde-3-phosphate dehydrogenase as positive con-
trols and positive internal standards as previously described (9).
To prevent amplification of genomic DNA, RNA samples were
treated with RQ1 DNAse before the reverse transcription step
(9). To further eliminate the possibility of amplification of ge-
nomic DNA, primer pairs were selected from different exons of
the perforin cDNA sequence (13). Samples of RT-PCR products
were separated by electrophoresis on agarose gels and blotted
onto nylon membranes for Southern blotting. Two human per-
forin cDNA probes (15–950 bp and 15–1,610 bp) were obtained
by PCR of a plasmid containing a full length human perforin
cDNA insert (pHP-10, gift of Dr. J.A. Trapani, University of
Melbourne, Melbourne, Australia), subcloned into the pGEM-T
plasmid (Promega, Southampton, UK) and sequenced on an auto-
mated sequencer (Applied Biosystems, Inc., Warrington, UK) to
confirm fidelity. Perforin cDNA probes were PCR-labelled with
FITC-dUTP and used for Southern blotting according to the
manufacturer’s protocol (Boehringer Mannheim, Lewes, Sussex,
UK). Hybridized membranes were then incubated with a rabbit
anti-FITC (Dako, Bucks, UK) followed by peroxidase-conjugated
anti–rabbit immunoglobulins (Biorad, Hertfordshire, UK), and
were finally developed using the enhanced chemiluminescence
system (Pierce and Warriner, Chester, UK).
 
Results
 
Astrocytes from Human Fetal Brain Cultures Constitutively Express
Perforin mRNA.
 
Total RNA was isolated from six different
cultures of human fetal astrocytes (passage 2–15) and sub-
jected to RT-PCR using multiple primer sets specific for
the human perforin cDNA sequence. All primer sets gave
products of the predicted size from astrocyte RNA (Fig. 1 
 
A
 
).
Perforin mRNA was also detected by RT-PCR of the two
glioma cell lines CB193 and T98G (data not shown). RNA
from human NK cell line (YT stimulated with IL2) gave
similar results, whereas RNA from other cell lines (Raji,
K562, and THP1) was consistently negative. Raji, K562,
Figure 2. Western blotting of
astrocyte extracts with monoclonal
antiperforin antibody. Detergent
extracts of a rat NK (RNK) cell
line (positive control), rat neona-
tal astrocytes, and human fetal as-
trocytes (passage 7, 2 3 107 cells/
ml) were run on SDS-PAGE (10%
acrylamide gel), Western blotted,
and probed with the monoclonal
antiperforin antibody (0.1–0.2
mg/ml). Bound antibody was de-
tected using goat anti–mouse im-
munoglobulins (1 out of 1,000) and developed using the enhanced
chemiluminescence detection system. A major band at 65 kD in the rat
NK cell lysates was the predicted size for perforin. A single major band of
65 kD was also detected in lysates of human fetal astrocytes (arrowed) but
not in neonatal rat astrocytes (28). 
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Figure 3. Immunodetection of perforin expressed in vitro by human
fetal astrocytes. (a) In a mixed culture of cells from human fetal brain (pas-
sage 0), only astrocytes were stained with monoclonal antiperforin anti-
body (stained in blue, alkaline phosphatase–conjugated antibody and
BCIP/NBT development), whereas fetal neurons growing in clusters (ar-
rowed) were always negative. The staining was obtained only after perme-
abilization of the cell membrane (ethanol–acetic acid fixation), indicating
that perforin was an intracellular protein. Original magnification: 3100.
(b and c) Pure fetal astrocyte cultures (passage 3) were stained for perforin
(mouse antibody, 1 mg/ml) and GFAP (rabbit antibody, 1 out of 4,000) fol-
lowed by FITC-conjugated donkey anti–mouse immunoglobulins (Jackson,
1 out of 400) and rhodamine-conjugated goat anti–rabbit immunoglobu-
lins (Jacksons, 1 out of 400). The fluorescence was photographed using
filters specific for rhodamine (GFAP; red fluorescence in b) or for FITC (per-
forin; green fluorescence in c). The staining confirmed that GFAP-positive
cells (b) were also perforin positive (c). However, it was clear that not all
GFAP-positive cells expressed perforin (arrowed). Original magnification:
3500. (d) Fetal astrocyte cultures (passage 3) were stained using the same
condition as described in b and c) and the fluorescence was photographed
using dual exposure of both rhodamine (GFAP) and FITC (perforin).
Cells positive for both fluorochromes (perforin- and GFAP-positive cells)
appeared yellow (original magnification: 3500). All perforin-positive cells
were GFAP-positive, but not all GFAP-positive cells were perforin-posi-
tive, indicating that only a proportion of astrocytes in culture expressed
perforin at detectable levels. No perforin-positive but GFAP-negative
cells were detected in fetal astrocyte cultures from passages 0 to 15. (e) No
specific FITC or rhodamine staining was detected when fetal astrocyte
cultures were incubated with irrelevant primary antibodies (mouse anti-
FH or rabbit anti-C4bp). Original magnification: 3500.
Figure 4. Immunostaining of human CB193 astrocytoma, YT NK cell
line, and adult astrocytes for perforin. (a–c) CB193 astrocytoma was cul-
tured on glass coverslip and stained using either irrelevant antibodies (a) or
double-stained with mouse antiperforin and rabbit anti-GFAP as de-
scribed in the legend of Fig. 3, b and c. The fluorescence was photo-
graphed using dual exposure (a and b). Cells positive for both fluoro-
chromes (perforin- and GFAP-positive cells) appeared yellow. (c) Part of
the same field as in b, but here the fluorescence was photographed only
in the FITC channel (green fluorescence, perforin staining). All perforin-pos-
itive cells were also GFAP-positive. (d and e) YT NK cell line used here
as a positive control. Cytospins were fixed in ethanol/acetic acid, and
double-stained using either irrelevant antibodies (mouse and rabbit; e) or
mouse antiperforin and rabbit anti-GFAP (d). The fluorescence was pho-
tographed using dual exposure. All the YT cells were perforin-positive
(green fluorescence, granular staining) and GFAP-negative. No specific stain-
ing was detected using irrelevant antibodies (e). Original magnification for
a–e: 3500. (f–j) Adult astrocytes cultured on glass coverslips were fixed
and stained using either rabbit anti-GFAP (f), mouse antiperforin (g and
h), or irrelevant antibodies (i and j), and were counterstained with hema-
toxylin. Specific binding of the antibodies was detected using peroxidase-
conjugated secondary antibodies (Biorad) and DAB development. Rabbit
anti-GFAP gave strong cytoplasmic staining of cells with long cellular
processes, confirming that these were adult astrocytes (f). These cells were
also strongly stained for CD44, CD56, and CD59 but not for CD68, GC,
or NSE (data not shown). Cytoplasmic staining for perforin was weakly
but reproducibly detected in the same population of cells (g and h). The
staining using irrelevant antibodies was consistently negative (i and j).
Original magnification for g–j: 31,250.455 Gasque et al.
and THP1 did not express perforin mRNA even after cell
stimulation with various cytokines (IFN-g, IL1-b, and
TNF-a) for a period of 24 h. Sequencing of the RT-PCR
products from astrocyte RNA confirmed their identity;
virtually all of the perforin coding sequence was included
in these products and differed from the published sequence
(13) at only one site, a C to T switch at position 490 (a si-
lent mutation, both codons specifying histidine; Fig. 1 B).
Only 1–5 3 104 cells were obtained from each adult brain
culture and this low number of cells was insufficient for
analysis of the expression of perforin mRNA by adult as-
trocytes. A compounding problem was that adult brain cul-
tures were a mixed culture containing microglia (CD681
cells) and fibroblasts (GFAP-negative flattened cells) and
only 40–50% of cells were astrocytes. Only the immunocy-
tochemical approach was suitable for the characterization of
the expression of perforin by adult astrocytes.
Astrocytes Express Perforin Protein. Western blotting of
cell extracts of human fetal astrocytes with specific antiper-
forin antibodies identified a positive band with a molecular
mass of z65 kD, identical to the major band obtained from
cell extracts of rat NK cells (Fig. 2). In contrast, rat neonatal
astrocytes (1–2-d-old newborn rat) did not express perforin
at a level detectable by Western blotting after 15 d in cul-
ture (passage 1; Fig. 2). The same number of cells were
used to prepare all cell lysates (2 3 107 cells/ml). Isolation
of lytically active perforin from astrocytes was attempted to
provide further proof of the identity of the molecule. De-
spite several attempts, no lytically active protein was ob-
tained.
Perforin Is Expressed by a Subpopulation of Astrocytes and Is
Not Stored in Granules. When mixed cultures from hu-
man fetal brain were stained with specific antiperforin anti-
bodies, only astrocytes were stained (Fig. 3 a). The staining
for perforin and GFAP was observed only when the cell
membrane was permeabilized by ethanol–acetic acid treat-
ment, suggesting that perforin was localized intracellularly.
Staining was relatively homogenous throughout the cyto-
plasm, in clear contrast to the strong granular staining in
YT NK cells, used here as a positive control (Fig. 4 d).
Other cells in the culture, microglia (CD681 cells), oligo-
dendrocytes (GC-positive cells, representing ,0.5% of the
total), fibroblasts (CD68- and GFAP-negative flattened cells),
and neurons (cluster of CD56high, CD44-negative cells over-
lying the astrocyte layer) were negative for perforin expres-
sion (data shown only for neurons, see arrow Fig. 3 a). Not all
fetal astrocytes in mixed (passage 0) or pure cultures (after
passage 3) were positive for perforin, as z20–30% of GFAP-
positive cells were perforin-negative (Fig. 3, b–d). The stain-
ing of fetal astrocytes for perforin was reproducible in dif-
ferent cultures (n .10), the proportion of positive cells was
consistent between cultures and no specific staining was
obtained with irrelevant rabbit or mouse antibody (Fig. 3 e).
Perforin was also expressed constitutively by two human
astrocytoma cell lines, T98G and CB193 (the latter shown
in Fig 4, b and c), and also by human adult astrocytes (Fig.
4, g and h) in a distribution similar to that in fetal astrocytes.
The staining in human adult astrocytes was weak in com-
parison with that in fetal astrocytes. Staining with control
irrelevant monoclonal or polyclonal antibodies was consis-
tently negative on all cell types (Fig. 4, a, e, i, and j). When
mouse and rat astrocytes (from 1–2-d-old neonates) were
stained for perforin using the monoclonal antibody, a very
weak staining was obtained on a small proportion of the
rodent astrocytes (,20% of the mixed culture; data not
shown).
Perforin expression by fetal astrocytes was confirmed by
FACSÒ analysis of permeabilized cells using the mouse anti-
Figure 5. FACSÒ analysis of YT NK cells and fetal astrocytes double
stained for perforin and GFAP. Cells in suspension were fixed and perme-
abilized and then simultaneously stained for perforin and GFAP using
mouse antiperforin (0.2 mg/100 ml/105 cells) and rabbit anti-GFAP (1/
200) followed by recombinant PE–conjugated goat anti-mouse immuno-
globulins (Dako, 1/100) and FITC-conjugated goat anti–rabbit immuno-
globulins (SeraLab, 1/100). FITC fluorescence and RPE fluorescence
were measured on a Becton Dickinson Facscan. Data are represented as
dot plots of a gated population R1 for each cell type (A) YT cells were
98% perforin positive but GFAP negative. Irrelevant (irr.) monoclonal
(Factor H) or polyclonal (CRP) antibodies gave no staining. (B) Fetal as-
trocytes were 98% positive for GFAP and 56% of the GFAP-positive cells
were also positive for perforin. Irrelevant antibodies were again negative.
Staining for CD59 was used here as a positive control.456 Expression of Perforin by Astrocytes during Brain Inflammation
perforin antibody and costaining for GFAP was confirmed
by using the rabbit anti-GFAP (Fig. 5 B). Between 50 and
60% of GFAP-positive cells from fetal astrocyte culture
passage 3 were also stained for perforin. The human NK
cell line YT and mouse CTLL-2 line were both 95–98%
positive for perforin using the same antibody, and ex-
pressed on average twice the amount of perforin (as esti-
mated by the mean of fluorescence) present in perforin-
positive human fetal brain astrocytes at passage 3 (Fig. 5 A).
When fetal astrocytes were stained using the rabbit anti-per-
forin  and the mouse anti-GFAP, again 50–60% of cells
were positive for both markers (data not shown). Perforin
was detected by FACSÒ only when the cell membrane was
permeabilized, confirming that perforin was not expressed
on the membrane and was present only in the cytoplasm.
Perforin and GFAP staining of fetal astrocytes was repro-
ducible (n 5 3). Staining for irrelevant primary antibodies,
mouse anti-CD11b, and rabbit anti-CRP was always nega-
tive in FACSÒ analysis of fetal astrocytes (Fig. 5 B). FACSÒ
analysis of the astrocytoma cell lines CB193 and T98G re-
vealed that .90% of cells were perforinhigh and GFAPweak
double-positive (data not shown). Insufficient cells were
obtained from adult brain cultures to be analyzed by FACSÒ
for perforin and GFAP expression.
Indirect immunofluorescence staining and confocal mi-
croscopy analysis confirmed that perforin staining in fetal
astrocytes was not associated with the cell membrane but
was diffusely distributed throughout the cytoplasm (Fig. 6,
b and c), in clear contrast with the granular cytoplasmic
staining of human YT and mouse CTL cells (Fig. 6, e and
f). At the electron microscopic level, perforin staining in
fetal astrocytes was cytoplasmic (Fig. 7, e and f), again con-
trasting with the distribution in mouse CTL, where per-
forin was restricted to dense cytoplasmic granules (Fig. 7 b)
as previously reported (14, 15). The distribution pattern for
astrocyte perforin in electron micrographs was suggestive of
an association with intracellular membrane networks.
Perforin Is Expressed by Reactive Astrocytes in Inflamed Human
Central Nervous System Tissues. The finding that perforin is
expressed by astrocytes and astrocyte cell lines in vitro pro-
voked us to examine whether perforin was also expressed
by these cells in vivo. Three samples of normal adult brain
(temporal brain) and two of fetal brain were analyzed in
this study. There was no evidence of brain inflammation in
these samples as indicated by the absence of astrogliosis
(GFAP and CD44 staining) or microgliosis (LN3 and CD14
staining). None of the normal human adult (Fig. 8 b) or fe-
tal brain frozen tissue sections (data not shown) stained with
antiperforin antibody, indicating that this molecule was not
Figure 6. Confocal microscopy confirms cytoplasmic localization of
perforin in fetal astrocytes. Fetal astrocytes and YT NK cells were perme-
abilized/fixed on glass coverslips and stained using either an irrelevant
antibody (mouse anti-FH; a and d) or mouse anti-perforin (1 mg/ml) fol-
lowed by FITC-conjugated donkey anti–mouse immunoglobulins (Jack-
son, 1/400). Fluorescence was analyzed on Leica TCS confocal micro-
scope. (a–c) Fetal astrocytes: a, negative control; b, extended focus image
of a field of fetal astrocytes stained for perforin; c, gallery of individual sec-
tion scans through a single fetal astrocyte stained for perforin. The lack of
membrane staining and cytoplasmic location of label is clear in the gallery.
(d–f) YT cells: d, negative control; e, extended focus image of a field of
YT cells stained for perforin (note the granular staining pattern); f, high
power view from e. Original magnification: 3500 for a, b, d, and e and
31,250 for c and f.
Figure 8. Immunodetection of perforin in normal human brain tissue.
Frozen tissue sections were stained (a) using an irrelevant antibody
(OX23, mouse antifactor H) or with mouse antibody against (b) perforin,
(c) HLA class II (clone LN3), or (d) CD44 (clone BRIC222) DAB/im-
munoperoxidase protocol and were counterstained using hematoxylin.
No specific staining for perforin was obtained in normal surgical brain,
whereas quiescent microglia and astrocytes were identified respectively by
the HLA class II and CD44 stainings (original magnification: 3500).457 Gasque et al.
expressed in normal brain and confirming a previous report
using a different monoclonal antiperforin antibody (16).
However, brain sections from several unrelated patholo-
gies, all presenting evidence of ongoing inflammation with
marked gliosis, including MS (Fig. 9, c, e, and f), AD (Fig.
9, h and i), Huntington’s disease (HD, Fig. 9 k), and PD
(Fig. 9 m), were positive for perforin, and the staining was
associated with large, GFAP-positive cells with a morpho-
logical appearance typical of reactive fibrillary astrocytes
(Fig. 9, a, g, j, and l). The perforin-positive cells were con-
firmed as astrocytes by double-staining of brain sections with
rabbit anti-GFAP in MS brain (Fig. 9, p–r; Fig. 10, a–d),
AD (Fig. 10, e and f), PD, and HD (data not shown). Reac-
tive astrocytes in chronic and semiacute MS were strongly
stained for perforin and no specific staining was detected
when irrelevant antibodies were applied on the tissue sec-
tions (mouse anti-FH and rabbit anti-C4bp, Fig. 9, b, d,
and o). In comparison, perforin staining on astrocytes was
weaker in the three different neurodegenerative disorders
examined. In MS, the majority but not all of the GFAP-
positive reactive astrocytes expressed perforin in their cyto-
plasm; interestingly, another population of small, rounded
cells were also found to be strongly perforin positive but
GFAP-negative (Fig. 9, c, e, and p, indicated by the arrow).
These small cells were present only in MS (plaque and
perivascular localization) but not in neurodegenerative dis-
orders (in temporal lobe and caudate nucleus). We suspect
that these cells represent perforin-positive NK and/or CTL
that are infiltrating the brain tissue in MS (for review see
reference 17).
Discussion
In this paper, we demonstrate by diverse methods that
cultured human fetal astrocytes, adult astrocytes, and astro-
cytoma cell lines constitutively express perforin. Astrocyte
perforin was indistinguishable from that in T and NK cell
lines upon Western blotting and the cDNA sequences were
essentially identical. In contrast to T and NK cell lines, as-
trocyte perforin was not contained within cytoplasmic
granules but was present throughout the cytoplasm, possi-
bly in association with the endoplasmic reticulum. Despite
numerous attempts and the relative abundance of perforin
in fetal astrocytes, we were unable to isolate lytically active
perforin from these cells. We believe that this failure was a
consequence of the limited numbers of primary astrocytes
that could be generated and the fact that human perforin
has extremely low activity in comparison with rat or mouse
perforin in the standard erythrocyte lysis assay system (our
unpublished observations). Indeed, we have been unable to
purify lytically active perforin even from human NK lines,
although we have successfully purified active rat and mouse
perforin.
We also show that perforin is expressed in inflamed hu-
man brain in diverse pathological states but is not expressed
in normal noninflamed fetal or adult brain. This latter ob-
servation suggests that products of inflammation cause the
upregulation of perforin expression in vivo and we are cur-
rently examining in vitro whether stimulation with inflam-
matory cytokines or other effector molecules can trigger
changes in the expression of perforin or induce its release
from astrocytes. Perforin expression in vivo is seen only in
the presence of pathology and specifically in association
with inflammation. It would be of interest to know when
during the course of the pathology expression of perforin
occurs. To address this issue we are currently attempting to
Figure 7. Electron microscopic analysis of perforin distribution in hu-
man fetal astrocytes and mouse CTL. Cells were fixed, immunogold
stained, and processed for electron microscopy as previously described
(12). The mouse cytotoxic T cell line (CTLL2) stained strongly for per-
forin in a granular cytoplasmic distribution (a, original magnification:
310,000). At higher power (b, original magnification: 322,000) the
granules were more clearly defined and it was apparent that there was lit-
tle or no staining outside the granules. No specific staining of mouse
CTLL2 was obtained using irrelevant mouse anti-FH (c, original magnifi-
cation: 320,000). Astrocytes did not contain detectable cytoplasmic gran-
ules (d, original magnification: 310,000) and immunogold staining dem-
onstrated that perforin was localized to the cytoplasm, perhaps in
association with intracellular membranous structures (e, original magnifi-
cation: 322,000). The nucleus (N) was not stained above background.
Double-immunostaining of cells for perforin (small gold particles) and
GFAP (large gold particles) confirmed that all perforin-positive cells were
also GFAP-positive (f, original magnification: 330,000). No specific
staining was obtained when fetal astrocytes were stained with irrelevant
mouse and rabbit primary antibodies (anti-FH and anti-CRP, respec-
tively;  g, original magnification: 313,000). gr, granules.458 Expression of Perforin by Astrocytes during Brain Inflammation
characterize the expression of perforin in rodent brains dur-
ing the induction of experimental neuropathology, includ-
ing experimental demyelination, brain infection, and stroke.
In these models we will be able to analyze during the time
course of the disease not only the cellular source of perforin
but also the site of expression in the central nervous system.
These studies will help to explain the role of perforin ex-
pression by astrocytes in the development of the various path-
ologies.
The cytoplasmic localization of perforin in astrocytes pre-
sents a conundrum. In cytotoxic T cells, dogma states that
perforin is contained within granules that are released only
after binding to target cell and only into the intracellular
space at the binding site. This event induces a localized per-
meability of the target membrane, allowing delivery of other
granule constituents, which induce killing, into the target cell
(1, 2). However, a second pathway of perforin release has
been demonstrated; a constitutive pathway in which newly
synthesized perforin is released directly from the cell with-
out prior inclusion in granules (18). This constitutive path-
way can mediate lytic killing of bystander cells, indicating
that perforin secreted in this manner is functional. Perforin
expressed in insect cells is also lytic despite the absence of
granules in these cells (19). Therefore, it is possible that
perforin is secreted constitutively by reactive astrocytes and
mediates cytotoxic and cytolytic effects on surrounding cells.
The physiological role of astrocyte perforin is likely to be
in immune defense and remodeling in the brain. The ab-
sence of neurological deficit in perforin knockout mice in-
dicates that the latter activity is not essential to normal brain
development (4, 5). In pathology, reactive astrocytes may
be induced to synthesize and secrete perforin in an undi-
rected, constitutive manner, placing resident brain cells at
risk. Astrocytes are relatively resistant to the lytic effects of
perforin (our unpublished data). However, oligodendro-
cytes, the myelin-producing cells in the brain, and neurons
are known to be extremely susceptible to perforin damage
(20, 21). Perforin generated locally by astrocytes may thus
contribute to the loss of oligodendrocytes in demyelination
and of neurons in neurodegeneration.
Figure 9. Immunodetection of perforin in inflamed human brain tis-
sue. Frozen tissue sections were stained either for perforin (mouse anti-
body; c, e, f, h, i, k, and m), GFAP (rabbit antibody; a, g, j, and l) or irrele-
vant antibodies (b and d) using a DAB/immunoperoxidase protocol (12)
and counterstained using hematoxylin. The diseases examined were MS
(a–e and o–r), AD (g–i), HD (j and k), and PD (l and m). In MS brain most
reactive astrocytes (GFAP-positive cells, a, original magnification 3500)
were stained for perforin (c, original magnification: 3500) and (e and f,
original magnification: 31,250). No specific staining of MS tissue sections
was obtained with irrelevant antibodies (rabbit anti-CRP [b] and mouse
anti-FH [d], original magnification: 3500). Small perforin-positive,
GFAP-negative cells were also identified in MS sections (2–3 cells/field at
3500 original magnification, panels c and e, indicated by the arrow). These
cells had no astrocytic features and were found in the inflammatory infil-
trate as well as in the demyelinating plaque. Perforin-positive–reactive as-
trocytes were also indentified in brain from AD (h and i, temporal lobe),
HD (k, caudate), and PD (m, temporal lobe). MS tissue (acute plaque) was
also double stained for perforin and GFAP without counterstaining (p–r).
The majority of GFAP positive cells (DAB development, brown staining)
were also perforin positive (BCIP/NBT development, blue precipitates).
The arrow in p indicates a single perforin-positive, GFAP-negative cell.
Tissue sections incubated with the appropriate control antibodies were
completely negative (o). Original magnification: 31,250 except for panel
o, original magnification: 3500.
Figure 10. Double immunofluorescence staining of MS and AD brains
for perforin and GFAP. Frozen sections of MS (a–d) and AD (e and f)
brain were stained using mouse antiperforin (FITC, green fluorescence) and
rabbit anti-GFAP (rhodamine, red fluorescence). In both diseases, all perforin-
positive cells (a, c, and e) were also GFAP positive (b, d, and f) (original
magnification: 31,250). Arrows in a and b and e and f indicate the same
cells in the two exposures. No staining was obtained with irrelevant anti-
bodies (data not shown).459 Gasque et al.
A second killing strategy used by cytotoxic T cells in-
volves interaction of Fas ligand with Fas on the target (3). It
has recently been reported that glial cells in MS brain and
in brain tumors express de novo Fas ligand and it has been
suggested that the interaction of glial Fas ligand with Fas on
target cells (notably on autoreactive T cells) might contrib-
ute to the control of immune defense in the brain (22, 23).
Although it was not clear from this report which glial cell
type expressed Fas ligand, the astrocyte is a prime candi-
date. We are currently analyzing expression of Fas ligand
by perforin-positive astrocytes in vitro and in vivo and ex-
amining the role of cytokines in the expression of these
molecules. Preliminary data indicates that astrocytes may
indeed express Fas ligand, further extending the similarity
with cytotoxic T cells. In addition, it has been recently
shown that oligodendrocytes express high level of Fas and
that anti-Fas monoclonal antibody or purified Fas-ligand
induced oligodendrocyte necrosis but not programmed cell
death (24). It was proposed that elevated Fas expression by
oligodendrocytes in MS might contribute to the loss of the
myelinating cells by interaction of Fas on the target cell
with Fas-ligand expressed by infiltrating CTLs and glia (24).
Reactive astrocytes in MS may thus be capable of killing oli-
godendrocytes through secretion of perforin and/or through
the Fas–Fas-ligand system. Endocytosis of oligodendrocytes
by reactive astrocytes in MS brain has been described for
many years (25–27). Whether this represents a mechanism
for the clearance of dead oligodendrocytes or a fundamen-
tal component of the proposed killing process remains to
be ascertained.
In summary, we report that astrocytes in vitro and in
vivo in the inflamed brain express perforin, a cytolytic pro-
tein which had previously been considered to be T and
NK cell–specific. We suggest that astrocytes may use CTL-
like mechanisms (perforin and Fas/Fas-ligand) to destroy
pathogens in the brain and that these mechanisms may also
contribute to the loss of glia and neurons in diverse neuro-
pathologies.
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